Why can growth hormone peptides raise blood sugar?
Growth hormone works against insulin, so anything that raises it can nudge glucose upward. The tesamorelin (Egrifta WR) label states plainly that treatment can result in glucose intolerance. In its trials, average A1C started at 5.3% in both groups, and by week 26, 5% of men on tesamorelin had an A1C of 6.5% or higher compared with 1% on placebo.
The picture is not one-sided. In a 12-month trial of tesamorelin in abdominally obese adults without HIV, fasting glucose, two-hour glucose and A1C did not change, while visceral fat fell. A 16-week study of a sermorelin-type GHRH peptide in men and women aged 55 to 71 also found fasting glucose and insulin unchanged. Effects vary from man to man, which is why testing beats guessing.
Which A1C results call for caution?
Your A1C is the starting point, because it shows your average blood sugar over the past few months. MedlinePlus lists the standard ranges below; each lab may report slightly different reference ranges.
| A1C result | What it means | How it shapes a growth hormone peptide decision |
|---|---|---|
| Below 5.7% | Normal | Standard baseline and follow-up glucose checks |
| 5.7% to 6.4% | Prediabetes | Possible, but the benefit has to justify the risk, with closer glucose follow-up |
| 6.5% or higher, stable on treatment | Diabetes | Case by case, coordinated with whoever manages your diabetes |
| Rising, or diabetes not under control | Diabetes needing attention | Growth hormone peptides wait until control improves |
These are not hard cutoffs from a guideline. The tesamorelin label does not set an A1C ceiling; it asks for a glucose evaluation before starting and periodic monitoring. Your provider weighs the number alongside your weight, your goals and how your A1C has moved over time. Our page on the HbA1c test for men explains the marker in more depth.
How is glucose monitored during treatment?
Monitoring starts before the first dose and continues for as long as you take the peptide. Before starting, the work-up includes fasting glucose and A1C along with IGF-1, which is covered on our page about blood work before peptide therapy.
On the tesamorelin plan, IGF-1 and glucose are rechecked at six to eight weeks and then every three months. Two more points from the label apply to men who already have diabetes:
- Retinopathy. Because tesamorelin raises IGF-1, the label advises watching for new or worsening diabetic eye disease.
- Medicine adjustments. Men with pre-existing diabetes may need their diabetes medicines changed.
If glucose intolerance develops and the peptide is not clearly working, the label advises considering stopping it. That is the practical rule: a peptide has to earn its place.
What about the other peptides on the menu?
Not every peptide acts on growth hormone. BPC-157, TB-500 and GHK-Cu work on tissue repair, and NAD+ is a coenzyme involved in cell energy. None of them is known to raise blood sugar the way growth hormone does, but human data on them are thin overall, and data in men with diabetes are thinner still. BPC-157 and TB-500 availability is also unsettled while the FDA finishes its review.
It also helps to know that some of the most-studied diabetes drugs are peptides. The Wegovy label describes semaglutide as a GLP-1 receptor agonist built on a peptide backbone. If weight and blood sugar are your main concerns, a medical weight loss plan with semaglutide or tirzepatide may fit better than a growth hormone peptide. Our page for men with type 2 diabetes walks through that route.
What happens at Ultimate Male when you have diabetes?
Tell us about your diabetes on the free phone call, including your latest A1C if you have it. Same-day labs at our San Gabriel or Downey clinic fill in the rest, with results in 24 to 48 hours. Your one-on-one consultation then covers whether a growth hormone peptide makes sense at your numbers, or whether a recovery peptide or a different plan suits you better.
If you go ahead, glucose checks are built into the follow-up schedule from the start. If your numbers drift, the plan changes. Read more about the full peptide therapy program, or book a consultation when you are ready.
